



CIAN HEALTHCARE LIMITED

(An ISO 9001:2015 & WHO GMP Certified Co.)

Corporate Office:

1st Floor, Premdeep Building, Above Latur Urban Co-Op. Bank Ltd.,
Lulla Nagar Chowk, Camp-Kondhwa Road, Pune - 411 040.
(Maharashtra) INDIA. Tel.: +91-20-41471234
Email: enquiry@cian.co, cianhealthcare@yahoo.co.in
Web: www.cian.co

Registered Office:

Milkant No. 3339, Block No.1 from South Side, C.S. No. 227/2+3A,
Harpale Park, Opp. Berger Paint, Phursungi, Tal. Haveli, Dist. Pune - 412 308,
(Maharashtra) INDIA. Tele-Fax.: +91-20-26982792

Factory:

Kh. No.: 248, Village Sisona, Bhagwanpur, Roorkee, Haridwar,
Pjn - 247 661. Uttarakhand, Tel.: 1332 235352

CIN: U24233PN2003PLC017563

To,
BSE Limited – CRD
P.J. Towers, Dalal Street,
Fort, Mumbai-400001

Date: 12th November, 2019

Script Code: 542678

Sub: SUBMISSION OF HALF YEARLY UNAUDITED FINANCIAL RESULTS FOR THE HALF YEAR ENDED 30TH SEPTEMBER, 2019 AS PER REGULATION 33 OF SEBI (LODR) REGULATIONS, 2015.

Dear Sir(s),

Pursuant to Regulation 33 of SEBI (LODR) Regulations, 2015, we are pleased to submit the Unaudited Financials Results for the Half year ended 30th September, 2019 in the form of PDF which was also approved by the Audit Committee and the Board of Directors of the Company at their meeting held on Tuesday, 12th November, 2019.

We are in process to file the aforesaid financial results in the form of XBRL within the stipulated time of 24 hours from the conclusion of the board meeting and the same shall also be hosted at the website of the Company.

You are requested to take on record the Unaudited Financial Results along with Limited Review Report for your reference and record.

Thanking You,

Yours Faithfully,

For Cian Healthcare Limited


Suraj Shrinivas Zanwar
Managing Director
DIN: 01304850



Encls: Unaudited Financial Results and Limited Review Report.

CIAN HEALTHCARE LIMITED
 Add: MILKAT NO.3339,BLOCK NO 1,FROM SOUTH SIDE,C S.NO. 227/2+3A,
 HARPALE PARK,OPP BERGER PAINT,PHURSUNGI, PUNE MH 412308 IN
 CIN :- U24233PN2003PLC017563

Statement of Profit and Loss for the Half Year ended September 30th,2019

(' in Lakhs)


Particulars	Half Year Ended			Year Ended
	September 30th 2019	Preceding 6 months ended on March 31st, 2019	Corresponding 6 months ended in previous year on September 30th, 2018	March 31st 2019
	Unaudited	Audited	Audited*	Audited
Revenue from Operations	2,941.30	2,970.71	3,273.47	6,244.17
Other Operating Revenue	(0.01)	(0.59)		(0.59)
Other Income	12.58	68.03	27.99	96.03
Total Income	2,953.88	3,038.15	3,301.46	6,339.61
EXPENSES				
Cost of Material Consumed	1,968.30	2,105.21	1,937.03	4,042.24
Operating Expenses	249.05	476.01		476.01
Employee Benefit expenses	249.35	228.93	333.65	562.57
Administrative Expenses	152.25	179.87	179.38	359.25
Finance Cost	292.71	273.57	236.05	509.62
Depreciation and amortization expenses	160.77	179.70	112.55	292.25
Total Expenses	3,072.43	3,443.30	2,798.65	6,241.95
Profit/(Loss) before exceptional items and tax	(118.56)	(405.15)	502.81	97.66
Exceptional Items	-	-3.58		(3.58)
Profit/(Loss) before tax	(118.56)	(408.74)	502.81	94.08
Tax expenses				
(1) Current tax	-	(118.59)	135.17	16.57
Mat credit entitlement				
(2) Deferred tax	-	11.98		11.98
Tax reversal of earlier year				
Profit (Loss) for the period from continuing operations	(118.56)	(302.12)	367.65	65.52
Profit(Loss) from discontinued operations	-			-
Tax expenses of discontinued operations				
Profit(Loss) from discontinued operations (after tax)	-	-	-	-
Profit/loss for the period	(118.56)	(302.12)	367.65	65.52
Other Comprehensive Income Items that will not be reclassified to profit or loss :				
Re-measurement gains/ (losses) on defined benefit plans	-			-
Income tax effect	-			-
Items that will be reclassified to profit or loss	-			-
Income tax relating to items that will be reclassified to profit or loss	-			-
Total other Comprehensive Income for the Year, net of tax	-	-	-	-
Total Comprehensive Income for the period (Comprising Profit (Loss) and Other Comprehensive Income for the period)	(118.56)	(302.12)	367.65	65.52
Earning per equity share (For continuing operations) :				
i) Basic (per share)	(0.51)	(1.76)	2.19	0.38
ii) Diluted (per share)	(0.51)	(1.76)	2.19	0.38
Earning per equity share (For discontinued operations):				
i) Basic (per share)	-			-
ii) Diluted (per share)	-			-
Earning per equity share (For discontinued & continuing operations):				
i) Basic (per share)	-			-
ii) Diluted (per share)	-			-

Notes:

- The above results were reviewed by an Audit Committee and thereafter taken on record by the Board of Directors in their Meeting on 12/11/2019
- There were no investor complaints known to the Company outstanding at the beginning of half year
- Previous period figures have been regrouped whenever necessary
- As the company was planning to go for IPO, the company's Financials for the half year ended on 30th September, 2018 were audited by M/s. Hanumantrao Lad & Associates, Chartered Accountants, Pune.
- Considering the nature of Company's business, there is only one reportable segment in accordance with the requirement of IND AS-108 on "Segment Reporting", hence separate disclosure of the segment information is not considered necessary.
- The Financial results for the half year and Year ended on 30th September 2019, are available on the website of the company (www.cian.co) and website of the Stock Exchange (www.bseindia.com)
- The above Financial results have been prepared in accordance with Accounting Standards (AS) as prescribed under section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014

For and on behalf of Board of Directors

Suraj Zanwar
 Director
 DIN: 01304850



Place: Pune
 Date: 12/11/2019

CIAN HEALTHCARE LIMITED

Add: MILKAT NO.3339,BLOCK NO.1,FROM SOUTH SIDE,C.S.NO. 227/2+3A,
HARPALE PARK,OPP.BERGER PAINT,PHURSUNGI, PUNE MH 412308 IN

CIN :- U24233PN2003PLC017563

Statement of Assets and Liabilities as at September 30th ,2019

(in Lakhs)

Particulars	As at September 30th 2019	As at 31st March 2019
ASSETS		
A Non-current assets		
(a) Property, Plant and Equipment	2,183.25	2,347.65
(b) Capital work-in- progress	2,260.05	637.11
(c) Property held for sale		
(b) Other Intangible Assets		
(c) Financial Assets		
(i) Investment in Shares of Dr. Smiths Biotech Private Limited	511.68	-
(d) Deferred tax assets (net)	-	-
(e) Other Non Current Assets	1,027.46	(222.52)
B Current assets		
(a) Inventories	1,643.19	1,594.92
(b) Financial Assets		
(i) Trade Receivables	2,351.71	2,061.31
(ii) Cash and Cash equivalents	158.15	99.67
(iii) Other Financial assets-FD with Banks	136.56	133.40
(iv) Other Financial assets		
(iii) Other Financial Assets	250.66	197.94
(c) Current tax assets (net)	-	-
(d) Other current assets	1,341.44	1,159.99
Total Assets	11,864.15	8,009.48
EQUITY AND LIABILITIES		
Equity		
(a) Equity Share capital	2,336.08	1,714.48
(b) Other Equity	3,507.37	455.77
Non-current liabilities		
(a) Financial Liabilities		
(i) Borrowings	2,526.68	2,286.48
(ii) Other financial liabilities		
(b) Provisions		
Deferred tax liabilities (net)	51.73	51.73
Other non-current liabilities	135.35	135.35
Current liabilities		
(a) Financial Liabilities		
(i) Borrowings	2,749.02	2,579.25
(i)(a) Trade payables-MSME	232.61	559.14
(i)(b) Trade payables-Others	126.87	
(ii) Other financial liabilities	97.55	97.55
(b) Other current liabilities		
(b) Other current liabilities	63.80	89.56
(c) Provisions	37.09	40.18
Total Equity and Liabilities	11,864.15	8,009.48

For and on behalf of Board of Directors

Suraj Zanwar
Director
DIN: 01304850



Place: Pune
Date:12/11/2019



Agarwal Mahesh K. & Co.
Chartered Accountants

📍 : 19, 5th Floor, Hansmani Society,
Nr. Dandekar Bridge, Navi Peth, Pune - 411 030.
✉ : agarwalmaheshkca@gmail.com
🌐 : www.agarwalmahesh.com
☎ : +91 9028109491, 9766909029, 7758883321

Independent Auditor's Review Report on unaudited half yearly and year to date financial results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To,
The Board of Directors
Cian Healthcare Limited
Pune

We have reviewed the accompanying statement of unaudited standalone financial results of Cian Healthcare Limited ('the Company') for the Half year ended September 30, 2019 and for the year-to-date results for the period from April 1, 2019 to September 30, 2019 ('the Statement'), being submitted by the Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended ('the Regulation').

This statement is the responsibility of the Company's Management and has been approved by the Board of directors And statement has been prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other recognized accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Agarwal Mahesh K & Co.

Chartered Accountants

FRN: 008007C

CA Ashish Boundia

Partner

Membership No. 156089

UDIN No.:- 19156089AAAAAU6963

Place: - Pune, Date: - 12.11.2019





CIAN HEALTHCARE LIMITED

(An ISO 9001:2015 & WHO GMP Certified Co.)

Corporate Office:

1st Floor, Premdeep Building, Above Latur Urban Co-Op. Bank Ltd.,
Lulla Nagar Chowk, Camp-Kondhwa Road, Pune - 411 040.
(Maharashtra) INDIA. Tel.: +91-20-41471234
Email: enquiry@cian.co, cianhealthcare@yahoo.co.in
Web: www.cian.co

Registered Office:

Milkant No. 3339, Block No.1 from South Side, C.S. No. 227/2+3A,
Harpale Park, Opp. Berger Paint, Phursungi, Tal. Haveli, Dist. Pune - 412 308,
(Maharashtra) INDIA. Tele-Fax.: +91-20-26982792

Factory:

Kh. No.: 248, Village.Sisona, Bhagwanpur, Roorkee, Haridwar,
Pin - 247 661. Uttarakhand, Tel.: 1332 235352

CIN: U24233PN2003PLC017563

To,
BSE Limited – CRD
P.J. Towers, Dalal Street,
Fort, Mumbai-400001

Date: 19/11/2019

Script Code: 542678

Sub: Outcome of Board Meeting.

Dear Sir(s),

With respect to our outcome uploaded on November 12th, 2019 regarding Unaudited Standalone Financial Results for the half year ended September 30, 2019 and Limited Review Report thereon, we had inadvertently not uploaded Cash Flow Statement for the half year ended September 30, 2019 in the note thereto. The same is attached herewith.

We request you to kindly take the same on your record.

Thanking You,

Yours Faithfully,

For Cian Healthcare Limited


Suraj Shrinivas Zanwar
Managing Director
DIN: 01304850



Encls: *Statement of Cash flow and Limited Review Report.*

CIAN HEALTHCARE LIMITED
 Add: MILKAT NO.3339,BLOCK NO.1,FROM SOUTH SIDE,C.S.NO. 227/2+3A,
 HARPALE PARK,OPP.BERGER PAINT,PHURSUNGI PUNE MH 412308 IN
 'CIN :- U24233PN2003PLC017563

Statement of Cash Flow for the Half Year Ended September 30th, 2019

(' in Lakhs)

Particulars	For the Period Ended September 30th, 2019	For the Year Ended March 31st ,2019
Cash Flow from operating activities		
Net Profit after tax	(118.56)	65.52
Adjustment for:		
- Depreciation and amortization expense	124.76	239.01
- Interest Expenses	287.28	485.65
- Deferred Tax Liability	-	11.98
- (Profit) / Loss on Sale/Disposal of assets	-	3.58
- Interest & Dividend received	(0.18)	(5.15)
Operating profit before working capital changes	293.31	800.59
(Increase) / Decrease in Other Non Current asset	(1,249.98)	623.26
(Increase) / Decrease in Inventories	(48.27)	(11.67)
(Increase) / Decrease in Trade receivables	(290.40)	495.54
(Increase) / Decrease in Other Current Assets	(181.45)	(984.36)
(Increase) / Decrease in Deferred Tax Asset	-	-
(Increase) / Decrease in other financial assets	(52.72)	27.76
Increase / (Decrease) in Provisions	(3.08)	18.17
Increase / (Decrease) in Trade Payables	(199.66)	36.50
Increase / (Decrease) in Other Financial Liabilities	-	97.55
Increase / (Decrease) in Other Current Liabilities	(25.77)	(32.91)
Cash generated from operations	(1,758.03)	1,070.43
Taxes paid	-	-
Net cash from operating activities	(1,758.03)	1,070.43
Cash flow from Investing activities		
Purchase of fixed assets	39.64	(592.91)
Investment in Shares	(511.68)	-
Proceeds from sale of fixed assets	-	2.60
(Increase) / Decrease in Capital Work in Progress	(1,622.94)	19.07
Interest & Dividend received	0.18	5.15
Proceeds / (Repayment) of Other Financial Assets	-	-
Net Cash flow from investing activities	(2,094.80)	(566.10)
Cash flow from financing activities		
Proceeds from issuance of Share Capital including share premium	3,791.76	330.77
Proceeds from long term borrowings	240.21	(173.16)
Proceeds / (Repayment) from / of short term borrowings	169.78	(2.00)
Proceeds from Share Application Money	-	-
Dividend Paid including dividend distribution tax	-	-
Proceeds / (Repayment) for Other Financial Assets	-	-
Interest paid	(287.28)	(485.65)
Net Cash flow from Financing Activities	3,914.46	(330.04)
Increase / (Decrease) in cash and cash equivalents	61.63	174.29
Cash and cash equivalents at beginning of the year	233.08	58.79
Cash and cash equivalents at end of the year	294.71	233.08

Notes :

- (i) Cash Flow Statement has been prepared under the indirect method as set out in the Accounting Standard (AS) 3 "Cash Flow Statements" as specified in the Companies (Accounting Standards) Rules, 2006.
- ii) The above cash- flow statement have been prepared under the indirect method setout in Ind AS 7, 'Statement of Cash flows' specified under section 133 of the Act read with rule 4 of the Companies (Indian Accounting Standard) Rules, 2015 and rule 4 of Companies (India Accounting Standard) Amendment Rules 2016.
- iii) Direct Tax paid is treated as arising from operating activities and are not bifurcated between investment and financing activities.
- iv) All figures in bracket indicates outflow of cash.
- v) Comparatives for September 2019 has been taken on the basis of audited financial statements as of 31st March 2019.

For and on behalf of Board of Directors

Suraj Zanwar
 Director
 DIN: 01304850

Place: Pune
 Date: 12/11/2019





Independent Auditor's Review Report on unaudited half yearly and year to date financial results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

The Board of Directors
Cian Healthcare Limited

We have reviewed the accompanying statement of unaudited standalone financial results of Cian Healthcare Limited ('the Company') for the half year ended September 30, 2019 and for the year-to-date results for the period from April 1, 2019 to September 30, 2019 ('the Statement'), being submitted by the Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended ('the Regulation'). Attention is drawn to the fact that the figures of net cash inflow/outflow for the corresponding half year ended September 30, 2018 and the corresponding year-to-date from April 1, 2018 to September 30, 2018 as reported in these financial results have been approved by the Company's Board of Directors but have not been subjected to review.

This statement is the responsibility of the Company's Management and has been approved by the Board of directors and statement has been prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other recognized accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to Believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Agarwal Mahesh K & Co.
Chartered Accountants
FRN: 008007C

CA Ashish Boundia
Partner

Membership No. 156089
UDIN No.:- 19156089AAAAAV9470
Place: - Pune, Date: - 16.11.2019

